LLY
Eli Lilly and Company
LLY has the edge over STE overall, supported by stronger fundamentals and stronger modeled upside.
STE
STERIS plc
STE has slightly lower modeled downside risk, despite its lower overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
STE Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Healthy |
STE's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
STE PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 22x | $253 | — |
| Current | 30x | $253 | — |
| Cheap | 33x | $279 | +9.9% |
| Fair | 40x | $336 | +33% |
| Expensive | 80x | $677 | +167% |
Historical ranges are pointers, not guarantees.
STE has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
STE Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for STE, with profitability improving.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over STE on earnings, with more consistent year-over-year improvement.
STE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $11.78 | +40% |
| Q3 2026 | $8.43 | +21% |
| Q2 2026 | $8.18 | +25% |
| Q1 2026 | $7.93 | +28% |
| Q4 2025 | $7.17 | +52% |
| Q3 2025 | $6.96 | +59% |
| Q2 2025 | $6.53 | +62% |
| Q1 2025 | $6.20 | +62% |
| Q4 2024 | $4.71 | -18% |
STE earned $8.43 per share over the past year, up 21% from the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over STE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over STE on profitability, with a higher operating margin.
STE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.6B | +8.8% |
| Q2 2026 | $1.5B | +7.3% |
| Q1 2026 | $1.6B | +7.3% |
| Q4 2025 | $1.5B | +9.2% |
| Q3 2025 | $1.5B | +9.9% |
| Q2 2025 | $1.4B | +8.7% |
| Q1 2025 | $1.5B | +4.3% |
| Q4 2024 | $1.4B | -1.8% |
STE's revenue has grown year over year for seven quarters in a row: $1.6B last quarter, up 8.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 19% | +0.3 points |
| Q2 2026 | 19% | +1.5 points |
| Q1 2026 | 20% | +5.3 points |
| Q4 2025 | 18% | +0.4 points |
| Q3 2025 | 18% | +1.7 points |
| Q2 2025 | 18% | +3.2 points |
| Q1 2025 | 15% | -2.7 points |
| Q4 2024 | 18% | +2.4 points |
STE's operating margin was 19% last quarter, about level with the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
STE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $212.9M | +5.8% |
| Q2 2026 | $279.6M | -14% |
| Q1 2026 | $245.2M | +29% |
| Q4 2025 | $199.5M | -18% |
| Q3 2025 | $201.3M | +35% |
| Q2 2025 | $326.4M | +67% |
| Q1 2025 | $189.9M | +16% |
| Q4 2024 | $243.6M | +41% |
STE's free cash flow has been positive every quarter for seven years: $937M over the past year, down 2.5% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
STE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -300K shares |
| 1 year | -1.2% | -1.2M shares |
| 3 years | -1.8% | -1.8M shares |
| 5 years | -3.1% | -3.1M shares |
| Available history | +14% | +12M shares |
STE has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $100.4M |
| Q2 2026 | $115.5M |
| Q1 2026 | $74.3M |
| Q4 2025 | $50.1M |
| Q3 2025 | $100.5M |
| Q2 2025 | $10.6M |
| Q1 2025 | $263,000 |
| Q4 2024 | $100.4M |
STE spent $340M buying back its own shares over the past year, up 61% from the year before.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
STE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.8x | Very low |
| Q2 2026 | 0.9x | Very low |
| Q1 2026 | 0.9x | Very low |
| Q4 2025 | 1.0x | Very low |
| Q3 2025 | 1.1x | Healthy |
| Q2 2025 | 1.2x | Healthy |
| Q1 2025 | 1.4x | Healthy |
| Q4 2024 | 1.5x | Healthy |
STE has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
STE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.7 | Neutral |
| Stochastic | 79.9 | Neutral |
STE's weekly RSI is 65 (neutral) and its Stochastic is 80 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
STE PE vs Healthcare Sector
| Metric | STE | Sector median | Relative |
|---|---|---|---|
| PE | 30x | 26x | 16% above |
| PE % | 10 | 29 | 19 pts below |
STE has the edge over LLY on valuation relative to its sector.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
STE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $227.4 | 11% above |
| 20 week MA | $224.8 | 13% above |
| 50 week MA | $230.0 | 10% above |
| 100 week MA | $231.6 | 9.4% above |
| 200 week MA | $224.2 | 13% above |
STE is in an uptrend: it's above all five of its weekly moving averages, and 13% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over STE on returns for 2026, with the stronger performance.
STE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $151.8 | $186.2 | +23% |
| 2021 | $186.2 | $241.1 | +29% |
| 2022 | $241.1 | $182.1 | -24% |
| 2023 | $182.1 | $219.9 | +21% |
| 2024 | $219.9 | $208.0 | -5.4% |
| 2025 | $208.0 | $255.4 | +23% |
| 2026 YTD | $255.4 | $253.4 | -0.8% |
STE has finished higher in four of the last six years. It's down 0.8% so far in 2026.